Cost Effectiveness of Denosumab versus Oral Bisphosphonates for Postmenopausal Osteoporosis in the US

In each PMO population examined, denosumab represented good value for money compared with branded bisphosphonates. Furthermore, denosumab was either cost effective or dominant compared with generic alendronate in the high-risk subgroups. </AbstractSection> Copyright Springer International Publishing Switzerland 2013

MoreLess

Year of publication:	2013
Authors:	Parthan, Anju ; Kruse, Morgan ; Yurgin, Nicole ; Huang, Joice ; Viswanathan, Hema ; Taylor, Douglas
Published in:	Applied Health Economics and Health Policy. - Springer, ISSN 1175-5652. - Vol. 11.2013, 5, p. 485-497
Publisher:	Springer

More details

Extent:	text/html
Type of publication:	Article
Source:	RePEc - Research Papers in Economics

Persistent link: https://www.econbiz.de/10011000724